Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447 | Chief People Officer | March 12, 2021 | March 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date March 12, 2021 · Filed March 19, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,679 |
Last balance in matching sequence
After 2021-03-12 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2021-03-12 · Grant · Acquired 5,000 · Balance 5,000 Row 2 · 2021-03-12 · Grant · Acquired 13,608 · Balance 18,608 Row 3 · 2021-03-12 · Disposition to issuer · Disposed 2,476 · Balance 16,132 Row 4 · 2021-03-12 · Disposition to issuer · Disposed 6,453 · Balance 9,679 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2021 Filed Mar 17, 2021 00:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 13,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000961 · primary_01.xml · derivative · entry 6 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,608 shares Expires 2021-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F4 · shares: The restricted stock units were granted on October 15, 2019. F3 · derivative.exercise_date: Vesting of restricted stock units was accelerated on March 12, 2021 by reason of Separation Agreement. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000961 · primary_01.xml · derivative · entry 5 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on October 12, 2018. F3 · derivative.exercise_date: Vesting of restricted stock units was accelerated on March 12, 2021 by reason of Separation Agreement. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Disposition to issuerCommon Stock | 6,535 | $12.09 | $79,008.15 |
DisclosureSEC source: 0001593968-21-000961 · primary_01.xml · nonDerivative · entry 4 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,429 Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantCommon Stock | 13,608 | $12.09 | $164,520.72 |
DisclosureSEC source: 0001593968-21-000961 · primary_01.xml · nonDerivative · entry 3 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,964 Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Disposition to issuerCommon Stock | 2,644 | $12.09 | $31,965.96 |
DisclosureSEC source: 0001593968-21-000961 · primary_01.xml · nonDerivative · entry 2 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,356 Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantCommon Stock | 5,000 | $12.09 | $60,450.00 |
DisclosureSEC source: 0001593968-21-000961 · primary_01.xml · nonDerivative · entry 1 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| March 12, 2021 Filed Mar 19, 2021 17:55 UTC Amendment | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Disposition to issuerCommon Stock | 6,453 | $12.09 | $78,016.77 |
DisclosureSEC source: 0001593968-21-000984 · primary_01.xml · nonDerivative · entry 4 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,679 Read SEC document |
| March 12, 2021 Filed Mar 19, 2021 17:55 UTC Amendment | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Disposition to issuerCommon Stock | 2,476 | $12.09 | $29,934.84 |
DisclosureSEC source: 0001593968-21-000984 · primary_01.xml · nonDerivative · entry 3 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,132 Read SEC document |
| March 12, 2021 Filed Mar 19, 2021 17:55 UTC Amendment | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantCommon Stock | 13,608 | $12.09 | $164,520.72 |
DisclosureSEC source: 0001593968-21-000984 · primary_01.xml · nonDerivative · entry 2 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,608 Read SEC document |
| March 12, 2021 Filed Mar 19, 2021 17:55 UTC Amendment | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantCommon Stock | 5,000 | $12.09 | $60,450.00 |
DisclosureSEC source: 0001593968-21-000984 · primary_01.xml · nonDerivative · entry 1 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| July 23, 2020 Filed Jul 28, 2020 00:01 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 9,920 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001593968-20-001670 · primary_01.xml · derivative · entry 2 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,920 Underlying: Common Stock · 9,920 shares Expires 2027-07-23 Read SEC document |
| July 23, 2020 Filed Jul 28, 2020 00:01 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantIncentive Stock Option (Right to Buy) · Derivative | 21,580 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001593968-20-001670 · primary_01.xml · derivative · entry 1 Kimball Dawn · CIK 0001791709 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,580 Underlying: Common Stock · 21,580 shares Expires 2027-07-23 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.